Divestment

Atos plea to creditor banks could backfire

3 Jan 2024

The 780 mln euro French IT group wants lenders to roll over its large debt pile. Plans to raise cash by selling Atos’s cybersecurity arm to Airbus suggest they should. But the company’s threats to seek legal protection if they don’t may give banks pause for thought.

Capital Calls: Eni’s green sale

22 Dec 2023

Concise views on global finance: The Italian energy major’s 10 bln euro valuation for its retail-and-renewables arm Plenitude is more likely to be recreated or exceeded if it avoids a rushed listing.

Price of Illumina’s Grail fail extends to board

19 Dec 2023

The gene-sequencing company finally conceded to selling the cancer-testing business it bought without regulatory approval for $7.1 bln. Its bravado will be costly, as Grail’s value has plummeted. Boss Francis deSouza already paid with his job; directors deserve to, as well.

Altice’s best hope will be a Middle East lifeline

18 Dec 2023

Telecoms tycoon Patrick Drahi is dismantling his empire to cope with a $60 bln debt wall. Attracting new investors may be tricky given low growth and a corruption scandal. Luckily Gulf states like the UAE and Saudi Arabia are flush with cash and keen to grab Western assets.

Vivendi takes slow road to unleashing value

14 Dec 2023

The 10 bln euro French media group may list pay-TV arm Canal Plus and advertising group Havas. That might help controlling shareholder Vincent Bolloré cut Vivendi’s conglomerate discount. A quicker ploy would address the fact that the rump is still a disparate jumble of assets.

Fourth is with Jana in communications-space wars

8 Dec 2023

The pushy hedge fund wants $5 bln fiber-network builder Frontier to auction itself. Three of its other recent campaigns in the industry – at CyrusOne, Vonage and Zayo – all led to deals. This one’s a tougher sell, but there’s probably a buyer willing to pay a modest premium.

Glencore’s split is yet to be copper-bottomed

6 Dec 2023

Having merged its coal assets with Canadian miner Teck’s, the $70 bln Swiss group is eyeing a spinoff. But boss Gary Nagle faces a tricky call on what to do with oil trading. And the appeal of a coal-clean metals split may hinge on whether Teck’s own separation creates value.

Bayer drug fail is symptom of growing breakup pain

20 Nov 2023

Shares in the 33 bln euro group fell 20% after it aborted a late-stage trial. Given drugs regularly fail, that’s excessive. Instead, investors’ main concern could be that a grim pharma outlook and litigation risk in Bayer's seeds unit mean a planned split may release less value.

Vodafone CEO M&A job boosts Italy deal confidence

14 Nov 2023

After successfully offloading the telco’s UK and Spanish arms, Margherita Della Valle may sell all or part of its slowing Italian business. Rival Iliad is the top contender. But the division is now worth perhaps 2 bln euros less than what tycoon Xavier Niel offered last year.

WWE McMahon’s slugfest loss is shareholder win

13 Nov 2023

The person behind the professional wrestling firm is selling shares just after it merged with Endeavor’s UFC. That could be a precursor to him bowing to Hollywood mogul Ari Emanuel. McMahon may feel it’s anticlimactic. But giving investors clarity on leadership is a victory.

Capital Calls: Bayer breakup

8 Nov 2023

Concise views on global finance: The 40 bln euro German seeds-to-drugs maker is considering splitting off its consumer or crop science divisions, but may still be left with a more unwieldy structure than its pharma peers.

Telecom Italia rival plan has too many pitfalls

3 Nov 2023

An ex-executive and a fund say the telco could raise 16 bln euros by offloading a Brazilian unit and other assets to slash its debt pile. That would spare it from selling its prized network to KKR. Yet bagging such valuations while executing a multi-step project looks tricky.

Sanofi sickness calls for activist tonic

2 Nov 2023

The pharma group lost nearly $27 bln of market value as it announced more investment in drugs. To keep investors happy, CEO Paul Hudson can sell its consumer business, step up dealmaking and buy back shares. Its long-suffering shareholder L’Oréal has reason to back bold action.

Capital Calls: McDonald’s resilience

30 Oct 2023

Concise views on global finance: The Golden Arches’ global same-store sales rose 9% thanks to both selective menu-price increases and smaller meals in different markets. It demonstrates the company’s ability to keep pace with disparate economies’ stretched consumers.

Music fund’s flat deal calls for major key change

25 Oct 2023

Shareholders are pushing Hipgnosis, run by industry veteran Merck Mercuriadis, to overhaul its board and cancel a $440 mln asset sale involving Blackstone. Poor governance and a discount value add weight to their case. A new management team could do better by selling the company.

Macquarie’s Norse saga sends telco breakup warning

17 Oct 2023

The Australian firm is mulling options for Danish operator TDC. A lengthy plan to separate its network from its consumer business left both units burdened by debt amid intense competition, which could deter buyers. Others looking to split, like Telecom Italia, may think twice.

One $16 bln deal travels lonely dual track

9 Oct 2023

Buyout shops GTCR and Apax may be exploring both a sale and an IPO for insurance broker AssuredPartners. Using two separate paths typically aims to create competitive tension and lift valuations. With equity, debt and M&A markets all cool, neither option poses a plausible threat.

Big Four scandals will derail breakup plans

5 Oct 2023

EY and PwC are dealing with issues in their tax and consulting units. In this Viewsroom podcast, Breakingviews columnists explain how falling valuations of rivals like Accenture as well as questions about the stability of consulting fees will mean these firms may stick together.

Intel’s latest breakup is a test for more to come

4 Oct 2023

The semiconductor giant will hive off more of its empire with IPO plans for its programmable chip unit. Weak markets dinged its last spinoff, but this separation can flout strong profit to highlight $18 bln of hidden value. It’s a dry run for a bigger split down the road.

Capital Calls: Sandoz

4 Oct 2023

Concise views on global finance: Shares in the generic drugs maker, which Swiss pharma giant Novartis has handed to investors in a spinoff, have started trading in Zurich.